Biotimize

Why doesn’t scientific research evolve as a solution to problems in Brazil? This answer even has a famous term among researchers: Valley of Death - a limbo where scientific research in the health area stagnates and does not advance to reach the clinical testing phases. The person who explains this is Cristiano Gonçalves, Director of Innovation and Technological Licensing at Butantan Institute. Given this scenario, Cristiano mentions the importance of the role of @biotimize , a startup in the Sthorm health hub, which recently opened a pioneering development complex operating in the “as a service” model (CDMO) under conditions of Good Laboratory Practices ( BPL), this means building a bridge over this valley so that research can develop within the country and reach the pre-clinical phase. #FromPaperToThePeople is a series of content about the importance of infrastructure for scaling research, allowing it to get off the ground and reach those in need. #Sthorm #FindTheOthers #Biotechnology #Biotimize #People

Norberto Prestes, master in Public Management with an emphasis on Biotechnology Network and currently executive president of the Brazilian Association of Pharmaceutical Inputs (abiquifi); Carolini Kaid, CEO of @vyrobio and scientist responsible for discovering that the genetically modified Zika Virus is capable of acting as a vector for treating tumors and other brain diseases; Marina Domenech, founder of SAIL for Health, CEO of Intrials Clinical Research and responsible for making the connection for the University of Oxford to open its first headquarters outside the United Kingdom in Brazil, talk about the importance of the opening of the new @biotimize laboratory in Piracicaba (São Paulo, Brazil) last week. The laboratory will be a pioneer in operating in the “as a service” model (CDMO) under conditions of Good Laboratory Practices (GLP), this means that in addition to offering services to universities and companies, it will also be the only one to operate with complete production from viruses, bacteria, yeast to mammalian cells. One of the first projects of the new Biotimize laboratory will be in partnership with Vyro Biotherapeutics: the production of the initial batch (phase 0) of the treatment that uses the Zika virus to attack brain tumors! This local production means more than just developing new treatments, it also means expanding our population’s access to advanced therapies at a lower cost, in addition to strengthening the national innovation ecosystem. “We are experiencing a milestone in the evolution of Brazilian bioscience.” Says Marina Domenech. #FindTheOthers #Sthorm #Biotechnology

Marina Domenech, founder of SAIL for Health, CEO of Intrials Clinical Research and responsible for making the connection for the University of Oxford to open its first headquarters outside the United Kingdom in Brazil Carolini Kaid, CEO of @vyrobio and scientist responsible for discovering that the genetically modified Zika Virus is capable of acting as a vector for treating tumors and other brain diseases; Norberto Prestes, master in Public Management with an emphasis on Biotechnology Network and currently executive president of the Brazilian Association of Pharmaceutical Inputs (abiquifi); talk about the importance of the opening of the new @biotimize laboratory in Piracicaba (São Paulo, Brazil) last week. The laboratory will be a pioneer in operating in the “as a service” model (CDMO) under conditions of Good Laboratory Practices (GLP), this means that in addition to offering services to universities and companies, it will also be the only one to operate with complete production from viruses, bacteria, yeast to mammalian cells. One of the first projects of the new Biotimize laboratory will be in partnership with Vyro Biotherapeutics: the production of the initial batch (phase 0) of the treatment that uses the Zika virus to attack brain tumors! This local production means more than just developing new treatments, it also means expanding our population’s access to advanced therapies at a lower cost, in addition to strengthening the national innovation ecosystem. “We are experiencing a milestone in the evolution of Brazilian bioscience.” Says Marina Domenech. #FindTheOthers #Sthorm #Biotechnology

A @biotimize , startup apoiada pela Sthorm, vem revolucionando o mercado de biotecnologia desde que se tornou a primeira CDMO da América Latina e se consolida como uma das grandes apostas no setor de deeptech no país. Como descreve a @epocanegocios : “Com um valor de mercado de grande destaque pelo Banco Interamericano de Desenvolvimento, a startup, com sede em Piracicaba, vem trilhando um caminho de sucesso e mostra a força da inovação científica em um dos principais polos de startups do país.” Seja em pesquisas de ponta ou soluções de biotecnologia de alta tecnologia, a Biotimize é um exemplo de como a ciência aplicada pode transformar o mercado e impactar vidas. Vamos juntos fortalecer o ecossistema de inovação no Brasil! #PoweredbySthorm #Biotecnologia #Inovação #Biotimize #Startups #Ciência #DeepTech #FindTheOthers

Why doesn’t scientific research evolve as a solution to problems in Brazil? This was one of the main topics at the 5th National Science, Technology and Innovation Conference, held in Brasília last week lead by @mcti Participating in this discussion and bringing solutions like Biotimize’s to standardize regulatory processes with a view to scaling and, consequently, advances in clinical trials is a huge step towards achieving innovation in the healthcare area. In addition to being alongside Dr. Carolini Kaid @vyrobio Fernando Barbosa @biotimize and Norberto Prestes @abiquifi we spoke with the Director of the National Health Surveillance Agency (ANVISA) , @anvisaoficial Meiruze Sousa Freitas. She highlights that “Our duty today is to bring this regulatory control and this standard closer to what is happening in universities and startups, effectively transforming it to benefit our country, whether by promoting more research, or by transforming these products into social value and added value, in addition to boosting our economy.” #FromPaperToThePeople is a series of content about the importance of infrastructure for scaling research, allowing it to get off the ground and reach those in need. #Sthorm #FindTheOthers #Biotechnology #Biotimize #People #ANVISA

Carolini Kaid, CEO of @vyrobio and scientist responsible for discovering that the genetically modified Zika Virus is capable of acting as a vector for treating tumors and other brain diseases; Norberto Prestes, master in Public Management with an emphasis on Biotechnology Network and currently executive president of the Brazilian Association of Pharmaceutical Inputs (abiquifi); Marina Domenech, founder of SAIL for Health, CEO of Intrials Clinical Research and responsible for making the connection for the University of Oxford to open its first headquarters outside the United Kingdom in Brazil, talk about the importance of the opening of the new @biotimize laboratory in Piracicaba (São Paulo, Brazil) last week. The laboratory will be a pioneer in operating in the “as a service” model (CDMO) under conditions of Good Laboratory Practices (GLP), this means that in addition to offering services to universities and companies, it will also be the only one to operate with complete production from viruses, bacteria, yeast to mammalian cells. One of the first projects of the new Biotimize laboratory will be in partnership with Vyro Biotherapeutics: the production of the initial batch (phase 0) of the treatment that uses the Zika virus to attack brain tumors! This local production means more than just developing new treatments, it also means expanding our population’s access to advanced therapies at a lower cost, in addition to strengthening the national innovation ecosystem. “We are experiencing a milestone in the evolution of Brazilian bioscience.” Says Marina Domenech. #FindTheOthers #Sthorm #Biotechnology